| Name |
Description |
Page Modified |
| A Novel Pharmacodynamic Model for Gatifloxacin vs. Salmonella Typhi in Timed Kill Curves |
Presented at the 2004 ASCPT Annual Meeting, Miami Beach, FL |
Fri Nov 02 13:15:24 EDT 2007 |
| Use of an in vitro Pharmacodynamic Model & Monte Carlo Simulation to Characterize the Pharmacokinetics and Pharmacodynamics of Gatifloxacin vs Salmonella Typhi |
Presented at the 2004 ECCMID Meeting, Czech Republic |
Fri Nov 02 13:15:24 EDT 2007 |
| Monte Carlo Simulation to Estimate in VITRO susceptibility breakpoints for Moxifloxacin, Gatifloxacin, and Levofloxacin against Staphylococcus Aureus |
Presented at the 2004 ICAAC Annual Meeting, Washington, DC |
Fri Nov 02 13:15:24 EDT 2007 |
| Development of a Novel Population Pharmacokinetic (PK)-Based Method to Describe the Time-Course of Gatifloxacin (GAT) Middle Ear Fluid (MEF) Concentrations in Children |
Presented at the the 2003 ICAAC Annual Meeting, Chicago, IL |
Mon Nov 05 11:30:50 EST 2007 |
| Serial Sinus Aspirate Sampling (SSAS): A Novel Technique for Evaluating Antimicrobial Therapy of Acute Maxillary Sinusitis (AMS) |
Presented at the 2003 ICAAC Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Population Pharmacokinetics (PK and Pharmacodynamics (PD) of Gatifloxacin (GAT) Plasma and MIddle Ear Fluid (MEF) Concentrations in Pediatric Patients with Acute Otitis Media Treatment Failures (AOM-TF) and/or Recurrent Otitis Media (ROM) |
Presented at the 2003 ICAAC Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Relationship Between Increased Levofloxacin Use and Decreased Susceptibility of Streptococcus pneumoniae : Report From the ARREST Program |
Presented at the 2003 ICAAC Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Pharmacokinetic Analysis of Gatifloxacin in Plasma and Sinus Aspirate During Treatment of Acute Maxillary Sinusitis |
Presented at the 2003 AAPS Annual Meeting |
Fri Nov 02 13:15:24 EDT 2007 |
| Gatifloxacin and the Elderly: PK-PD Rationale for Potential Age-Related Dose Reduction |
Presented at the 2002 IDSA Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Use of Monte Carlo Simulation to Evaluate the Antibacterial Activity of Garenoxacin Against Gram-Positive Bacteria |
Presented at the 2002 ICAAC Annual Meeting, San Diego, CA |
Fri Nov 02 13:15:24 EDT 2007 |
| Pharmacodynamics of Gatifloxacin 400 mg, Levofloxacin 500 mg and 750 mg and Moxifloxacin 400 mg Against Ciprofloxacin-Resistant Streptococcus Pneumoniae |
Presented at the 2002 IDSA Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Minimum Efficacy and Mutation Prevention Exposure Target Attainment Rates Against Streptococcus pneumoniae for Levofloxacin 500 mg and 750 mg and Moxifloxacin 400 mg |
Presented at the 2002 IDSA Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Gatifloxacin in Children with Recurrent Otitis Media (ROM): Application of Real-Time Data Assembly (RTDA) and Sparse PK Sampling in Clinical Development |
Presented at the 2001 ICAAC Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |